2

Docket No.: 500862001500

AMENDMENTS TO THE CLAIMS

194.1 198.1 124/108.1 128.1

MUK

Claim 1 (Currently amended): An modified anti-viral peptide-albumin conjugate comprising

a peptide having been modified to contain an anti-viral peptide comprising a maleimide containing group which is reactive with cysteine 34 of serum albumin to form a stable covalent bond, said peptide comprising and an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, wherein said sequence exhibiting exhibits an anti-viral activity against human immunodeficiency virus (HIV) wherein and said peptide is covalently bonded to cysteine 34 of serum albumin through said maleimide containing group to form said peptidealbumin conjugate, wherein the ratio of peptide to serum albumin in said conjugate is 1:1.

Claim 2 (canceled)

Claim 3 (canceled)

2

Claim 4 (Currently amended) The modified anti-viral peptide-albumin conjugate of claim 1 wherein said peptide is DP 107 and comprises the amino acid sequence [[of]]is SEQ ID NO:2.

Claim 5 (canceled)

3

Claim & (Currently amended): The modified anti-viral peptide-albumin conjugate of claim 1 wherein said peptide amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 7-18 (canceled)

4

3

Docket No.: 500862001500

Claim 16 (Currently amended): A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, an medified anti-viral peptide-albumin conjugate including a peptide having been medified to contain a comprising an anti-viral peptide comprising a maleimide containing group and which is reactive with cysteine 34 of serum albumin to form a stable covalent bend, said peptide comprises an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, wherein said sequence exhibiting exhibits an anti-viral activity against human immunodeficiency virus (HIV) wherein and said peptide is covalently bonded to cysteine 34 of serum albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to serum albumin in said conjugate is 1:1.

Claim 20 (canceled)

Claim 21 (Currently amended): The composition of claim 20 12 wherein said peptide is DP 107 comprising the amino acid sequence [[of]]is SEQ ID NO:2.

Claims 22-30 (canceled)

Claim 31 (Currently amended): The composition of claim 39 wherein said peptide eemprises an amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 32-35 (canceled)

Claim 36 (Currently amended): A composition comprising the modified anti-viral peptide_albumin conjugate of claim 1 in a physiologically acceptable medium.

Claim 3/7 (canceled)

Docket No.: 500862001500

Claim 38 (Currently amended): The composition of claim 36 wherein said modified antiviral peptide comprises the amino acid sequence [[of]]is SEQ ID NO:2.

Claim 39 (Currently amended): The composition of claim 36 wherein said modified antiviral peptide comprises an amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claim 40-55 (canceled)

Please add the following new claims:

Claim 56 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:147.

Claim 57 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:148.

Claim 56 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:149.

Claim 59 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:179.

Claim 60 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:180.

Claim of (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:181.

Claim 6/2 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:542.

Docket No.: 500862001500

NO. 724——P. 10——

Claim 63 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:543.

Claim 64 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:544.

Claim 65 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:545.

Claim 66 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:147.

Claim 61 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:148.

Claim 68 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:149.

Claim \$9 (new): The composition of claim 18 wherein said amino acid sequence is SEQ ID NO:179.

Claim 70 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:180.

Claim /1 (new): The composition of claim 1/2 wherein said amino acid sequence is SEQ ID NO:181.

Claim 1/2 (new): The composition of claim 1/2 wherein said amino acid sequence is SEQ ID NO:542.

Claim 73 (new): The composition of claim 1/9 wherein said amino acid sequence is SEQ ID NO:543.

6

Docket No.: 500862001500

28

Claim 74 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:544.

Claim 75 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:545.